b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1)
b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1). A2 and… Read More »b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1)